FDA Approves Bayer's MEDRAD Centargo CT Injection System

Bayer revealed that it received approval from the U.S. Food and Drug Administration (FDA) for its MEDRAD® Centargo CT Injection System, a groundbreaking multi-patient injector that enhances workflow efficiency through design elements that align with Bayer's range of products, particularly in high-volume CT environments.

Bayer’s MEDRAD® Centargo CT Injection System provides benefits for radiology departments as the US encounters a shortage of radiology technologists alongside an increasing need for medical imaging.

“Since its launch in 2020, Centargo has served approximately seven million patients across 49 markets world-wide. The FDA clearance further demonstrates our nearly 40 years of CT innovation and commitment to delivering effective technologies to improve diagnostic imaging for patients,” said Sven Schmidt, Head of Region Americas Radiology at Bayer. “We know radiologists today are facing a continuously increasing workload, and the automation, integration and mobility of the MEDRAD® Centargo CT Injection System helps radiology staff do more with less, allowing them more time to focus on their patients.”

“We've found the ease of using the Centargo injection system is having a real impact on our technologists' ability to do their work quickly and with less worry," says Mike Minoo, Manager, CT and Interventional Radiology at Sunnybrook. "For example, because I am spending less time preparing the injector and its components, I have more time to spend with the patient, increasing their comfort level and understanding of the procedure. The quality of this interaction provides a better overall experience for both myself as a clinician and the patient."